SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has scheduled its second quarter 2025 financial results announcement for August 4, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET. Investors can access the call through registration and listen to the live webcast on SI-BONE's investor relations website. The webcast recording will remain available for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), un'azienda di dispositivi medici specializzata nei disturbi sacropelvici, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 4 agosto 2025 dopo la chiusura del mercato.
L'azienda terrà una conference call alle 13:30 PT / 16:30 ET. Gli investitori potranno accedere alla chiamata previa registrazione e seguire la diretta webcast sul sito web delle relazioni con gli investitori di SI-BONE. La registrazione della webcast resterà disponibile per la visione in replica per almeno 90 giorni dopo l'evento.
SI-BONE (Nasdaq: SIBN), una empresa de dispositivos médicos enfocada en trastornos sacropélvicos, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 4 de agosto de 2025 después del cierre del mercado.
La compañía realizará una llamada conferencia a las 1:30 PM PT / 4:30 PM ET. Los inversores pueden acceder a la llamada mediante registro y escuchar la transmisión en vivo en el sitio web de relaciones con inversores de SI-BONE. La grabación de la transmisión permanecerá disponible para reproducción durante al menos 90 días después del evento.
SI-BONE (나스닥: SIBN)은 천골골반 장애에 중점을 둔 의료기기 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 4일 장 마감 후로 예정했습니다.
회사는 오후 1:30 PT / 오후 4:30 ET에 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 등록을 통해 콜에 접속할 수 있으며 SI-BONE 투자자 관계 웹사이트에서 라이브 웹캐스트를 청취할 수 있습니다. 웹캐스트 녹화는 이벤트 이후 최소 90일 동안 다시보기로 제공됩니다.
SI-BONE (Nasdaq : SIBN), une entreprise de dispositifs médicaux spécialisée dans les troubles sacropelviens, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 4 août 2025 après la clôture du marché.
L'entreprise organisera une conférence téléphonique à 13h30 PT / 16h30 ET. Les investisseurs pourront accéder à l'appel via une inscription et écouter la diffusion en direct sur le site des relations investisseurs de SI-BONE. L'enregistrement de la diffusion restera disponible en replay pendant au moins 90 jours après l'événement.
SI-BONE (Nasdaq: SIBN), ein Medizintechnikunternehmen mit Fokus auf sakropelvine Erkrankungen, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 4. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird eine Telefonkonferenz um 13:30 Uhr PT / 16:30 Uhr ET abhalten. Investoren können über eine Registrierung an dem Anruf teilnehmen und den Live-Webcast auf der Investor-Relations-Website von SI-BONE verfolgen. Die Aufzeichnung des Webcasts wird mindestens 90 Tage nach der Veranstaltung zur Wiedergabe verfügbar sein.
- None.
- None.
SANTA CLARA, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the second quarter of 2025 after market close on Monday, August 4, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/fnam2tia/. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,500 physicians in performing a total of over 125,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 175 peer reviewed publications including two randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.
For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.
SI-BONE, Sacropelvic Solutions, iFuse Implant System®, iFuse Bedrock Granite, and iFuse TORQ, are registered trademarks, and iFuse 3D, iFuse TORQ TNT, and iFuse INTRA are trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.
Investor Contact: Saqib Iqbal investors@si-bone.com
FAQ
When will SI-BONE (SIBN) report Q2 2025 earnings?
What time is SI-BONE's Q2 2025 earnings conference call?
How can investors access SI-BONE's Q2 2025 earnings call?
How long will SI-BONE's Q2 2025 earnings webcast be available for replay?
